Australia

Zeniquin® Tablets

Expand All
  • Broad-spectrum oral fluoroquinolone antibacterial for dogs and cats.

  • Effective for treating skin and soft-tissue infections in dogs and cats and for urinary tract infections in dogs.

  • Treating infections in dogs associated with bacteria susceptible to marbofloxacin.

    Effective in treating bacterial skin and soft-tissue infections in dogs and canine urinary tract infections (cystitis) associated with bacteria susceptible to marbofloxacin.

    Skin and soft-tissue infections in cats.

  • Powerful antibacterial therapy resource for small-animal practitioners, when first line therapy has failed or culture and sensitivity results indicate in vitro cure.

    Excellent safety profile.

    Convenient once-a-day dosing and easy-to-swallow film-coated tablets improve client compliance.

    Available in 3 formulations for flexible dosing for small to giant-sized breeds.

    Longer half life than any other fluoroquinolone, based on available label comparisons of small animal veterinary fluoroquinolones.

    Superior pharmacokinetic profile, which indicates increased likelihood of clinical cure.

  • Recommended dosage for oral administration to dogs and cats is 2.75 mg marbofloxacin per kg of bodyweight once daily. The dosage may be safely increased to 5.5 mg/kg for 2-3 days beyond cessation of clinical signs for a maximum of 30 days.

    For treatment of urinary tract infections in dogs, Zeniquin® Tablets should be administered at a dosage of 2.75 mg/kg once daily for 10-14 days. If no improvement is noted within 5 days, diagnosis should be re-evaluated and a different course of therapy considered.

  • As a class, fluoroquinolones have been shown to potentially cause arthropathy in immature animals, particularly dogs. Marbofloxacin is contraindicated in immature dogs during the rapid growth phase (small and medium breeds up to 8 months of age, large breeds up to 12 months of age and giant breeds up to 18 months of age).

    Marbofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones.

    The following clinical signs were reported during clinical field studies in dogs receiving marbofloxacin at dosages up to 5.5 mg/kg daily: decreased or loss of appetite (5.4%), decreased activity (4.4%), and vomiting (2.9%). The following signs were reported in less than 1% of cases in dogs: increased thirst, soft stool/diarrhea, behavioral changes, shivering/shaking/tremors and ataxia.

    Law restricts this drug to use by or on order of a licensed veterinarian. (S4)

    Law prohibits the extra-label use of this drug in food-producing animals.

    The following clinical signs were reported during clinical field studies in cats receiving 5.5 mg/kg daily diarrhea (2.1%) and soft stool (1.4%) vomiting was reported in <1% of cases.